Medicare utilization — ADRIAN TALAT BADDAR (MD)
Calendar year 2023 · data refreshed 2026-05-27
| HCPCS | Description | Services | Beneficiaries | Allowed | Payment |
|---|---|---|---|---|---|
| J7328 | Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg | 23,016 | 48 | $0 | $13,803 |
| J7329 | Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg | 3,525 | 52 | $0 | $23,875 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 3,495 | 466 | $0 | $2,888 |
| J0897 | Injection, denosumab, 1 mg | 2,700 | 32 | $0 | $49,927 |
| 97110 | Therapy procedure using exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes | 1,258 | 277 | $0 | $24,018 |
Service volume and Medicare payment amounts do not indicate quality of care, patient outcomes, or fraud. Data reflects Medicare fee-for-service only.
Source: CMS public data · Not endorsed by CMS · Beneficiary counts under 11 are suppressed in source data ·